Velia Chiara Di Maio

Multiclass <scp>HCV</scp> resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapies

Velia Chiara Di Maio, Valeria Cento, Ilaria Lenci et al. · Liver International · 2017 · 90 citations · Full text

Life Sciences, Infectious Diseases, Clinical Pharmacology +11

Hepatitis C Virus Genetic Variability and the Presence of NS5B Resistance-Associated Mutations as Natural Polymorphisms in Selected Genotypes Could Affect the Response to NS5B Inhibitors

Velia Chiara Di Maio, Valeria Cento, Carmen Mirabelli et al. · Antimicrobial Agents and Chemotherapy · 2014 · 57 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1–4 in Italy

Ada Bertoli, M.C. Sorbo, M. Aragri et al. · Scientific Reports · 2018 · 48 citations · Full text

Life Sciences, Genetics, Infectious Diseases +17

Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

Julia Dietz, Velia Chiara Di Maio, Adolfo de Salazar et al. · Journal of Hepatology · 2020 · 45 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +10

Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

A Howe, Chaturaka Rodrigo, Evan B. Cunningham et al. · JHEP Reports · 2022 · 42 citations · Full text

Medicine, Pharmacology, Clinical Pharmacology +16